Parallel Advisors’s Immix Biopharma IMMX Stock Holding History

Parallel Advisors’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,890	Closed	-$7.77K	–	3428
2023 Q2	$7.77K	Buy	+2,890	New	+$6.05K	﹤0.01%	2275

Other funds holding IMMX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Imprint Wealth Mount Pleasant, South Carolina $21.9M AUM

MAWA

Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICG

InterOcean Capital Group Nashville, Tennessee $4.19B AUM 26.29% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Parallel Advisors's IMMX Position: Q3 2023 in Review

Parallel Advisors sold out of Immix Biopharma (IMMX) in Q3 2023, closing a stake of 2,890 shares — an estimated $7.77K sold.

Parallel Advisors first reported a position in IMMX in Q2 2023 and held it in 1 quarter. The position peaked at $7.77K in Q2 2023. 16 funds tracked by Wall St. Rank hold IMMX as of Q3 2023.

Parallel Advisors reported no remaining Immix Biopharma position as of Q3 2023 after selling out during the quarter.
Parallel Advisors sold 2,890 Immix Biopharma shares in Q3 2023, an estimated $7.77K.
Parallel Advisors first reported a position in Immix Biopharma in Q2 2023 and held it in 1 quarter.
Parallel Advisors's Immix Biopharma position peaked at $7.77K in Q2 2023.
16 funds tracked by Wall St. Rank held Immix Biopharma as of Q3 2023.

Based on Parallel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.